Goodwin

Arman Oruc

Deals
10
Latest
May 2026
Most deals in
Biotech

Firm

  • Goodwin Law firm · 2026 · 10 deals
Deals by year
Arman Oruc: deals by year051020252026 YTD: 9 M&A2026 YTD: 1 Equity raisings102026 YTDM&AEquity raisings

Often works with

Deals

Deals dated after 30 September 2026 are still being collected.

Columns
Deals Arman Oruc was named on, most recent first
May 2026 Anagram Therapeutics ––StakeLegal adviser to Anagram Therapeutics (target)Announced–Biotech+2Stake in Anagram Therapeutics
May 2026 Perfuse Therapeutics –BayerAcquisitionLegal adviser to Perfuse Therapeutics (target)Announced300.0Biotech+2Bayer acquisition of Perfuse Therapeutics
May 2026 LimmaTech Biologics AG –Eli Lilly and CompanyAcquisitionLegal adviser to LimmaTech Biologics AG (target)Pending780.0BiotechEli Lilly and Company acquisition of LimmaTech Biologics AG
Apr 2026 Kelonia Therapeutics –Eli Lilly and CompanyAcquisitionLegal adviser to Kelonia Therapeutics (target)Announced7,000.0Biotech+2Eli Lilly and Company acquisition of Kelonia Therapeutics
Apr 2026 Obsidian Therapeutics ––PlacementLegal adviser to Obsidian TherapeuticsCompleted350.0Biotech+2Obsidian Therapeutics placement
Apr 2026 Obsidian Therapeutics –Galera TherapeuticsMergerLegal adviser to Obsidian TherapeuticsCompleted413.5Biotech+2Galera Therapeutics and Obsidian Therapeutics merger
Apr 2026 Tubulis EQT Life Sciences (LSP 7 fund)Gilead SciencesAcquisitionLegal adviser to Tubulis (target)Announced3,150.0Biotech+2Gilead Sciences acquisition of Tubulis
Mar 2026 Ouro Medicines –GileadAcquisitionLegal adviser to Ouro Medicines (target)Announced1,675.0Biotech+1Gilead acquisition of Ouro Medicines
Mar 2026 Pikavation SynnovationNovartisAcquisitionLegal adviser to Synnovation Therapeutics (seller)Announced2,000.0Biotech+2Novartis acquisition of Pikavation
Feb 2026 Orna Therapeutics –Eli Lilly and CompanyAcquisitionLegal adviser to Orna Therapeutics (target)Announced2,400.0Biotech+1Eli Lilly and Company acquisition of Orna Therapeutics

Deals where Arman Oruc is named on the firm's deal team, by the firm or the press.

Suggest a correction

A missing deal, a wrong firm, a move between firms, or two different people shown as one. A link to a public source helps.